Skip to main content

Table 4 Toxic and adverse effects in patients in the two study groups (according to NCI-CTCAE v3.0)

From: Clinical research of intraperitoneal implantation of sustained-release 5-fluorouracil in advanced colorectal cancer

Parameter Group 1 Group 2
I II III IV V I II III IV V
WBC 4 2 1 0 0 5 1 0 0 0
Platelet count 1 1 0 0 0 2 0 0 0 0
Bleeding 0 0 0 0 0 0 0 0 0 0
Renal toxicity 0 0 0 0 0 0 0 0 0 0
Hepatotoxicity 1 1 0 0 0 2 1 0 0 0
Fever (post-operation >7 days) 3 0 0 0 0 2 1 0 0 0
Infection 9 3 0 0 0 12 2 0 0 0
Diarrhea 0 0 0 0 0 0 0 0 0 0
Vomiting 1 0 0 0 0 1 1 0 0 0
Constipation 0 0 0 0 0 1 0 0 00 0
Cardiac function 0 0 0 0 0 0 0 0 0 0
Pneumonia (X-ray) 4 0 0 0 0 4 1 0 0 0
Peripheral numbness 0 0 0 0 0 0 0 0 0 0
Allergic reaction 0 0 0 0 0 1 0 0 0 0
Abdominal ache (post-operation >7 days) 5 2 0 0 0 5 1 0 0 0
  1. When toxic and adverse events were classified according to the NCI-CTCAE v3.0, there were no significant differences between the two groups. The most common were 7 cases of abdominal ache in group 1 and 6 cases in group 2; 2 cases of hepatotoxicity in group 1 and 3 cases in group 2; and 12 cases of infection in group 1 and 14 cases in group 2. All of the reported events were grade I or II and therefore were mild or moderate
  2. NCI-CTCAE National Cancer Institute common terminology criteria for adverse events